STOCK TITAN

Equillium Inc - EQ STOCK NEWS

Welcome to our dedicated news page for Equillium (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Equillium's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Equillium's position in the market.

Rhea-AI Summary
Equillium announces enrollment completion for Phase 1b study in lupus nephritis
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
-
Rhea-AI Summary
Equillium Inc. announces presentation at the 18th Annual Peptide Therapeutics Symposium highlighting EQ302, a second generation orally deliverable multi-cytokine inhibitor in development to target IL-15 and IL-21.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.58%
Tags
-
News
Rhea-AI Summary
Equillium, Inc. will host a virtual analyst and investor day on October 16, 2023, providing a review of its pipeline and a focus on its lead asset, EQ101, currently in a Phase 2 clinical trial for alopecia areata.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Equillium, Inc. will present at the JonesTrading 2023 Healthcare Summit, discussing industry trends and strategic alliances.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
conferences
-
Rhea-AI Summary
Equillium, Inc. to present at Cantor Fitzgerald Global Healthcare Conference and LD Micro Main Event Conference. Management will provide an overview of the Company’s multi-cytokine inhibitor platform and upcoming milestones.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
conferences
-
Rhea-AI Summary
Equillium, Inc. to host investor meetings at Wells Fargo Healthcare Conference and present at H.C. Wainwright 25th Annual Global Investor Conference. Management to provide overview of EQ101 and EQ102 treatments, as well as itolizumab development. Webcast access available for H.C. Wainwright conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.9%
Tags
-
Rhea-AI Summary
Equillium, Inc. has authorized the repurchase of up to $7.5 million of its common stock. The program is expected to fund the company's clinical development efforts and does not affect its cash runway. The repurchases may be made on the open market or through privately negotiated transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
buyback
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.24%
Tags
none
Equillium Inc

Nasdaq:EQ

EQ Rankings

EQ Stock Data

65.22M
17.76M
36.42%
21.65%
1.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
La Jolla

About EQ

equillium, inc., a clinical-stage biotechnology company, develops products for autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor cd6, which is in phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and phase 1 clinical trial for the treatment of asthma and lupus nephritis. the company was formerly known as attenuate biopharmaceuticals, inc. and changed its name to equillium, inc. in may 2017. equillium, inc. was founded in 2017 and is headquartered in la jolla, california.